89bio Inc. (ETNB)
6.41
0.13 (2.07%)
At close: Jan 15, 2025, 11:18 AM
Company Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases.
Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis.
The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
89bio Inc.
| Country | United States |
| IPO Date | Nov 11, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 70 |
| CEO | Rohan Palekar |
Contact Details
Address: 142 Sansome Street San Francisco, California United States | |
| Website | https://www.89bio.com |
Stock Details
| Ticker Symbol | ETNB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001785173 |
| CUSIP Number | 282559103 |
| ISIN Number | US2825591033 |
| Employer ID | 83-1114349 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Rohan Palekar | Chief Executive Officer & Director |
| Francis W. Sarena | Chief Operating Officer |
| Ryan Stephen Martins | Chief Financial Officer |
| Amanda Kurihara | Vice President of People & Culture |
| Annie J. Chang M.B.A. | Vice President of Investor Relations & Corporate Communications |
| Dr. Harry Mansbach M.D. | Chief Medical Officer |
| Melissa Abel | Senior Vice President of Commercial Strategy |
| Paul Shin | Senior Vice President of R&D Operations |
| Quoc Le-Nguyen | Chief Technical Officer |
| Shiva K. Natarajan CPA | Senior Vice President of Finance & Principal Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 13, 2025 | 8-K | Current Report |
| Dec 23, 2024 | SCHEDULE 13G | Filing |
| Dec 16, 2024 | 4 | Filing |
| Dec 16, 2024 | 4 | Filing |
| Dec 16, 2024 | 4 | Filing |
| Dec 16, 2024 | 8-K | Current Report |
| Dec 10, 2024 | 4 | Filing |
| Dec 09, 2024 | 4 | Filing |
| Nov 25, 2024 | 4 | Filing |
| Nov 18, 2024 | SC 13D/A | [Amend] Filing |